Researchers have developed a three-dimensional ‘organ on a chip’ which enables real-time continuous monitoring of cells, and could be used to develop new treatments for disease while reducing the number of animals used in research.
A new synthetic enzyme, crafted from DNA rather than protein, ‘flips’ lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells.
Researchers from the UK and Denmark have developed a new method to predict the physical stability of drug candidates, which could help with the development of new and more effective medicines for patients. The technology has been licensed to Cambridge spin-out company TeraView, who are developing it for use in the pharmaceutical industry in order to make medicines that are more easily released in the body.
Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, University College London and the University of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.